drugset
drugset / Trial / NCT02915198

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

NCT02915198 ↗

Phase 4 Recruiting 7410 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.

Timeline

Start
2023-04-03
Primary completion
2029-09-28
Completion
2029-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg —

Indications

atherosclerosis prediabetes syndrome